Benefit–risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophrenia

The purpose of this study was to conduct a post-hoc benefit–risk assessment of paliperidone palmitate once-monthly (PP1M) injectable versus oral paliperidone extended-release (ER) in schizophrenia maintenance treatment. The Benefit–Risk Action Team framework was used to structure the analysis based...

Descripción completa

Detalles Bibliográficos
Autores principales: Levitan, Bennett, Markowitz, Michael, Turkoz, Ibrahim, Fu, Dong-Jing, Gopal, Srihari, Alphs, Larry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams And Wilkins 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5049945/
https://www.ncbi.nlm.nih.gov/pubmed/27434314
http://dx.doi.org/10.1097/YIC.0000000000000141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5049945/
https://www.ncbi.nlm.nih.gov/pubmed/27434314
http://dx.doi.org/10.1097/YIC.0000000000000141

Ejemplares similares